Monoclonal Antibody Treatment for Canine Parvovirus
Elanco Animal Health Incorporated an agreement with Kindred Biosciences to acquire exclusive global rights to KIND-030, a first-of-its-kind monoclonal antibody being developed for the treatment and prevention of canine parvovirus, a deadly disease impacts at least 250,000 puppies annually in the U.S., according to Banfield Pet Hospital.
While vaccination or prevention is clearly the best strategy regarding canine parvovirus, there has been no approved treatment available.
Data from BluePearl Specialty and Emergency Pet Hospital notes a 70 percent increase in positive parvovirus cases in their hospitals due to increased adoptions and higher volumes of dogs moving through shelters during the SARS CoV-2 pandemic.
In a press release, Aaron Schacht, executive vice president, Innovation, Regulatory and Business Development at Elanco said, “With parvovirus on the rise, it’s more important than ever to bring a new treatment option to veterinarians for this devastating and deadly disease. Given our significant global access to veterinarians and pet owners, Elanco has a proven track record of partnering with biotech companies, leveraging our R&D capabilities and our skilled team of experts to advance and prove the potential of novel treatments like KIND-030. We’re excited to establish this important partnership with KindredBio to develop and commercialize this novel monoclonal antibody.”
From the Kindred Bio website, KIND-030, a monoclonal antibody targeting canine parvovirus (CPV), is being pursued for two indications: Prophylactic therapy to prevent clinical signs of CPV infection, and treatment of established CPV infection.
KIND-030 is planned to be a cost-effective alternative to supportive care to treat canine parvovirus. Note, for another virus, the novel corona virus that causes COVID-19 monoclonal antibody is a treatment, though this treatment may be hard to find for people.
KindredBio’s CEO, Richard Chin, M.D. said in the release, “We are excited to partner with Elanco, known as an innovation partner of choice for its proven track record in effective collaboration to commercialize external innovation. We believe KIND-030 can transform the way parvovirus infections are treated and prevented.”
CPV is highly contagious and is spread from dog to dog by direct or indirect contact with their feces, and is most common among puppies. Vaccines can prevent this infection, but mortality can reach 91 percent in untreated cases and is considered life-threatening even when treated.